Kangfeng Biotechnology - B (06922.HK) announced its interim performance for the six months ended in June, with revenue recording 19.48 million RMB (same below), an increase of 3% year-on-year. The loss expanded from 43.4 million yuan in the same period last year to 52.17 million yuan, with a loss per share of 22 cents. No interim dividend will be distributed.
《業績》康灃生物(06922.HK)中期虧損擴至5,217萬人民幣
The performance of Jiangfeng Bio (06922.HK) in the first half of the year has expanded to a loss of 52.17 million Chinese yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated